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Dysregulated mitophagy and
mitochondrial organization in optic
atrophy due to OPA1 mutations
ABSTRACT
Objective: To investigate mitophagy in 5 patients with severe dominantly inherited optic atrophy
(DOA), caused by depletion of OPA1 (a protein that is essential for mitochondrial fusion), com-
pared with healthy controls.
Methods: Patients with severe DOA (DOA plus) had peripheral neuropathy, cognitive regression,
and epilepsy in addition to loss of vision. We quantified mitophagy in dermal fibroblasts, using 2
high throughput imaging systems, by visualizing colocalization of mitochondrial fragments with
engulfing autophagosomes.
Results: Fibroblasts from 3 biallelic OPA1(2/2) patients with severe DOA had increased mito-
chondrial fragmentation and mitochondrial DNA (mtDNA)–depleted cells due to decreased levels
of OPA1 protein. Similarly, in siRNA-treated control fibroblasts, profound OPA1 knockdown
caused mitochondrial fragmentation, loss of mtDNA, impaired mitochondrial function, and mito-
chondrial mislocalization. Compared to controls, basal mitophagy (abundance of autophago-
somes colocalizing with mitochondria) was increased in (1) biallelic patients, (2) monoallelic
patients with DOA plus, and (3) OPA1 siRNA–treated control cultures. Mitophagic flux was also
increased. Genetic knockdown of the mitophagy protein ATG7 confirmed this by eliminating
differences between patient and control fibroblasts.
Conclusions: We demonstrated increased mitophagy and excessive mitochondrial fragmentation
in primary human cultures associated with DOA plus due to biallelic OPA1 mutations. We pre-
viously found that increased mitophagy (mitochondrial recycling) was associated with visual loss
in another mitochondrial optic neuropathy, Leber hereditary optic neuropathy (LHON). Combined
with our LHON findings, this implicates excessive mitochondrial fragmentation, dysregulated
mitophagy, and impaired response to energetic stress in the pathogenesis of mitochondrial optic
neuropathies, potentially linked with mitochondrial mislocalization and mtDNA depletion.
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GLOSSARY
DOA 5 dominantly inherited optic atrophy; IMM 5 inner mitochondrial membrane; LC3 5 light chain 3; LHON 5 Leber
hereditary optic neuropathy; MMP 5 mitochondrial membrane potential; mtDNA 5 mitochondrial DNA; MFN2 5 mitofusin
2; MTOC 5 microtubule-organizing center; PINK1 5 PTEN-induced putative kinase 1; TMRM 5 tetramethyl rhodamine
methyl ester.
Autosomal dominant optic atrophy (DOA) is the commonest autosomal form of mitochon-
drial optic neuropathy, with most patients harboring pathogenic mutations in the optic
atrophy 1 (OPA1) gene. OPA1 mutations cause dominantly inherited progressive visual
failure in the first 2 decades, secondary to optic nerve neurodegeneration. Strikingly, a sub-
group of patients develops a multisystemic neurologic phenotype, known as DOA plus.
Other obligate OPA1 mutation carriers are visually asymptomatic. The mode of inheritance
is autosomal dominant in the majority of cases, either haploinsufficiency or dominant-
negative, with DOA plus patients frequently harboring missense mutations in the GTPase
domain.
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OPA1 appears to regulate mitochondrial
quality control mediated through mitophagy,1
a specialized type of autophagy.2 Mitophagy is
one among several types of mitochondrial
quality control,3 and the only pathway known
to turn over whole mitochondrial genomes. It
is crucial for normal development4 and allows
dysfunctional mitochondrial DNA (mtDNA)
to be recycled instead of triggering cell death.5
We previously demonstrated increased mi-
tophagy in fibroblasts from patients with Leb-
er hereditary optic neuropathy (LHON).6
This was attenuated by idebenone, which con-
ferred symptomatic improvement.6 To clarify
whether increased mitophagy is an important
feature of mitochondrial optic neuropathies,
we investigated the role ofOPA1 in mitophagy
in primary OPA1 mutant fibroblasts from 5
patients in 3 families with severe DOA plus
phenotypes. We also studied the effects of
siRNA-mediated knockdown of OPA1 in pri-
mary human control fibroblasts. Because
OPA1 deficiency is widely expressed, fibro-
blasts have been extensively used to model
the cellular mechanisms occurring in retinal
ganglion and muscle cells in this multisystem
disease.7,8
METHODS Mitophagy is a sequence of events in which a struc-
ture known as the autophagosome9 forms and engulfs spent mito-
chondria in a process facilitated by microtubule motors. The
autophagosome is then transported towards the cellular
microtubule-organizing center10 (MTOC) and fuses with
lysosomes, ultimately resulting in the degradation of its
enclosed cargo. We therefore quantified mitophagy by counting
autophagosomes, that is, characteristic puncta positive for
microtubule-associated protein 1 light chain 3 (LC3), and
colocalizing with mitochondrial markers.2
Standard protocol approvals, registrations, and patient
consents. Ethics: Patient and control fibroblast lines. Patient
and control samples were obtained with informed consent with
the approval of the UK National Research Ethics Service (South
Central-Berkshire and Newcastle and North Tyneside), or of the
Ethical Committee of the Foundation Carlo Besta Institute of
Neurology, according to the Declaration of Helsinki. Donors
included 5 patients with DOA plus phenotypes, 5 other family
members sharing mutant OPA1 alleles, and 20 normal controls.
Pedigrees of 3 biallelic patients harboring compound heterozy-
gousOPA1mutations (strictly described as semi-dominant11–13) are
presented in figure 1A. A summary of the clinical presentations
and genotypes of all patients (illustrated in figure 1B) are pre-
sented in the table. This includes chronic progressive external
ophthalmoplegia with an apparent defect in mtDNA mainte-
nance14,15 that remains unexplained (DOA plus OPA1[1/2]1
and 2, table). Further details of the clinical presentation, a cranial
MRI scan of the biallelic patients, and the likely effects on protein
are presented in appendix e-1 and figure e-1, A and B, at
Neurology.org. Following the convention of previous authors,13
we designated the 3 biallelic patients DOA plus because each had
clinical and electrophysiologic evidence of both peripheral and
optic neuropathy.
Immunofluorescence and live cell imaging. Cells were pro-
cessed for histochemistry, immunofluorescence, or live staining
with PicoGreen and tetramethyl rhodamine methyl ester
(TMRM) as previously described (appendix e-2). We used 2
high-throughput imaging systems for detecting mitophagy: the
established IN Cell 100016 and ImageStream, which we
validated (figure e-2).
Statistical analysis. Statistical analysis is detailed in appendix e-2.
RESULTS Biallelic OPA1 mutant patients and families.
We studied primary fibroblasts, carrying biallelic
OPA1 mutations, from patients and transmitting rel-
atives belonging to 2 families (see table for an expla-
nation of nomenclature, figure 1A for pedigree, and
appendix e-1 for additional clinical details). The pro-
band of family 1, DOA plus OPA1(2/2)1, is a 17-
year-old boy presenting with a severe OPA1
phenotype (figure 1A). DOA plus OPA1(2/2)1
carries a c.2708_2711delTTAG p.V903Gfs*3
mutation, found in the paternal grandfather, in
trans with a maternal c.661G.A p.E221K change
(OPA1[1/2]1 and N1, respectively, in figure 1A).
In family 2, biallelic patients DOA plus OPA1(2/2)
2 and 3 both had a paternal c.2353delC p.
Q785Sfs*15 and a maternal c.2869C.T, p.H957Y
mutation (figure 1, A and B; see figure e-1B for
PolyPhen analysis). No other relatives were affected.
The frameshift mutation in family 1 is a well-
established pathogenic mutation.17 None of these
mutations involves the GTPase domain of OPA1,
classically implicated in syndromic DOA,13
examples of which were identified in monoallelic
DOA plus families 3 and 4 (table).
Fibroblasts from DOA plus patients have a fragmented
mitochondrial network with occasional mtDNA-depleted
cells. We investigated the cellular phenotype of
probands, transmitting relatives, and controls. We
visualized both mtDNA and mitochondria by using
the DNA-specific dye PicoGreen and the
mitochondrial membrane potential (MMP)–
sensitive dye TMRM.18 The mitochondrial network
had a fragmented morphology in a small minority of
cells from patients DOA plus OPA1(2/2)1–3, but it
was normal in other cells (figure 1C). Using high-
throughput imaging (figure 1D), we showed that
mitochondria in fibroblasts from biallelic and
monoallelic DOA plus patients (DOA plus OPA1
[2/2]1–3 and DOA plus OPA1[1/2]1–2) were
significantly more fragmented than mitochondria
from 6 controls (p 5 0.005 and 0.01, respectively,
figure e-3A). Using PicoGreen to visualize mtDNA,19
we found a significant increase in cells that were
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Figure 1 Genetic analysis of a family with a very severe dominantly inherited optic atrophy (DOA) plus phenotype
(A) Pedigrees of families 1 and 2. (B) OPA1 gene structure. Diagrammatic representation of the OPA1 gene. The diagram indicates the location both of
mutations resulting in DOA plus syndromes as described8 (small symbols) and of the mutations reported in this study (large symbols; highlighting corre-
sponds to pedigree). Mutation type: stars (missense); squares (nonsense); circles (splice site); triangles (deletion). CC 5 coiled-coil domain; GE 5 GTPase
effector domain; UTR5 untranslated region. (C) PicoGreen/tetramethyl rhodamine methyl ester (TMRM) costaining of live fibroblasts from biallelic DOA plus
OPA1(2/2)1–3 patients, and their symptom-free mothers (N1 and OPA1[1/2]2; see A). PicoGreen stains DNA and TMRM is sensitive to mitochondrial
Continued
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depleted of mtDNA in biallelic patients compared to
controls with IN Cell 1000 (p, 0.001, figure 1E). In
all cultures, these mtDNA-depleted cells had
fragmented mitochondria with a lower membrane
potential (figure 1E.a and 1E.b) than control cells.
Intermediate mitochondrial fragmentation and
mtDNA depletion were present in fibroblast
cultures from DOA OPA1(1/2) but not from
non-syndromic DOA (figure e-3A) or the
asymptomatic, obligate carrier relatives of the
biallelic patients.
OPA1 knockdown causes mtDNA depletion and alters
the distribution of mitochondria in control cells. To
determine whether mitochondrial DNA depletion is
a consistent effect of OPA1 knockdown20 and
whether it would be sufficient to affect mitochondrial
function, we then knocked down OPA1 in control
fibroblasts using a pan-OPA1-specific siRNA,21 thus
modeling the reduction in full-length OPA1 protein
in patient cells. Compared to the reduced OPA1
protein levels seen in the patient fibroblasts, the
siRNA achieved a more profound reduction (figure
2A), and knockdown cells underwent fragmentation
and perinuclear clustering of the mitochondrial
network (figure 2B).
Next, we visualized both mtDNA and mitochon-
dria in the OPA1 siRNA-treated cells,18 and found
a marked loss of mtDNA (figure 2C). In these cells,
mitochondria clustered in the perinuclear region (fig-
ure 2, B–D), and often displayed high TMRM fluo-
rescence, suggesting increased MMP or increased
organelle density. We confirmed these findings using
anti-DNA immunoglobulin M/MitoTracker colabel-
ing of mtDNA (figure 2C) and real-time PCR (figure
2E). Despite the considerable mtDNA depletion,
COX activity was largely preserved at 5 days, but
reduced by 14 days (figure 2D).
By using an antibody against pericentrin, we
showed that the perinuclear mitochondrial clusters
consistently colocalized with the MTOC (figure
2F.a). As well as being crucial for neuronal survival
and function, microtubule-dependent transport me-
diates efficient encounters of autophagosomes with
lysosomes,22 which cluster near the nucleus under
conditions such as nutrient deprivation.15,23 A similar
clustering of mitochondria occurs by overexpressing
tau,24 because tau inhibits microtubule-dependent
plus-end-directed transport of mitochondria. Thus,
we hypothesized that clustering of mitochondria at
the MTOC in knockdown cells may be due to either
decreased plus-end or increased minus-end transport
caused by excessive fragmentation and mitophagy. To
test this idea, we exposed cells to microtubule-
disrupting drugs. Nocodazole, which disassembles
microtubules, rescued the perinuclear clustering so
that the distribution of mitochondria resembled that
in control cells (figure 2F.b). Exposure to taxotere
(disrupts MTOC) and cytochalasin D (depolymerizes
actin) disrupted perinuclear mitochondrial clustering,
supporting our assertion that it depends on micro-
tubules and MTOC. For a more detailed explanation,
see figure e-3B. Together, these results demonstrate
that OPA1 knockdown in primary human fibroblasts
causes disruption of the mitochondrial network, par-
tial mtDNA depletion, and microtubule-dependent
rearrangement of the mitochondrial distribution.
High-throughput imaging shows that patient fibroblasts
harbor increased autophagosomes colocalizing with
mitochondria compared to controls. We reasoned that
the depletion of mtDNA associated with OPA1
knockdown could be due either to slowed mtDNA
synthesis or to increased mtDNA turnover and
therefore investigated whether OPA1 insufficiency/
dysfunction had affected mitophagy. We measured
total mitochondrial autophagy irrespective of Parkin
and PINK1 using 2 high-throughput imaging
systems, ImageStream and IN Cell 1000,16 which
are established methods for quantifying autophagy
and mitophagy. In each of these, antibodies to
LC3 and Tom20 are used to immunolabel
autophagosomes and mitochondria, respectively. In
figure e-2D, we show that ImageStream and IN
Cell 1000 techniques are comparable.
Fibroblasts from DOA plus OPA1(2/2)2 and 3
(figure 3A.a) and DOA plus OPA1(2/2)1 (figure
3A.b and 3A.c) patients all harbored significantly
more LC3-positive puncta colocalizing with mito-
chondrial fragments, and hence more mitophagy than
those from the control using ImageStream. Colocal-
ization of the lysosomal marker, LyosID, with LC3
puncta is used to demonstrate autolysosomes, a later
stage of mitophagy than autophagosomes (figure 3A.a
Figure 1 legend, continued:
membrane potential. Nuclei of cells exhibiting mitochondrial fragmentation are marked with an asterisk. PicoGreen panel shows the same field as the high-
magnification TMRM panel. TMRM staining of cells from biallelic DOA plus patients with abnormal mitochondrial fragmentation were often also depleted of
mtDNA (E), but this was more marked in the siRNA-treated cell cultures in figure 2. (D) We used IN Cell 1000 to measure the mean mitochondrial length in
fibroblast cultures, stained either with TMRMand PicoGreen25,26 or with antibody tomitochondrial protein Tom20. Cultures were grown for 3 days in 96-well
plates in triplicate. To quantify the degree of mitochondrial fragmentation, we measured the average mitochondrial length in each cell and plotted a fre-
quency distribution. This shows that while the modal length was similar in both groups, the per cell average mitochondrial length was shorter in biallelic
patients (D.a) than controls (D.b) (see also figure e-3). (E) Cells depleted of mtDNA are increased (E.a) and have a lower membrane potential by TMRM staining
(E.b). Error bars are 1 standard error. Asterisks indicate p, 0.001 compared to controls (2-tailed t test). Each bar represents between 400 and 1,500 cells.
mtDNA 5 mitochondrial DNA.
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and 3A.b, respectively). Increased colocalization of
mitochondria with LC3/LyosID-positive autolyso-
somes supported an increase in mitophagy in these
biallelic patients (figure 3A.c). Figure 3B shows that
the increase in mean level of mitophagy in the group
of all DOA plus patients (combining biallelic and
monoallelic) compared to controls over 4 indepen-
dent experiments was significantly increased (p 5
0.035). It was not increased in nonsyndromic
monoallelic relatives. Analysis of control fibroblasts
treated with OPA1 siRNA also suggested that
mitophagy was increased compared with scramble
siRNA (figure 3C.a). This is consistent with
the increase in LC3-II abundance on Western blot
analysis (figure 3C.b).
Similarly, quantitative fluorescence microscopy
using IN Cell 100016 confirmed that LC3 puncta
colocalizing with mitochondria were increased in
cells from biallelic patients at baseline, compared
to controls (figure 3D). Similar increases in basal
mitophagy were seen in fibroblasts from 2 mono-
allelic DOA plus OPA1(1/2) patients who had
GTPase domain mutations (DOA plus OPA1
[1/2]1 and DOA plus OPA1[1/2]2), but were
comparable to control levels in cells from 5 individ-
uals who had monoallelic OPA1 mutations (N1,
N2, OPA1[1/2]1, OPA1[1/2]2, and DOA
OPA1[1/2]).
Mitophagic flux is increased in fibroblasts from biallelic
DOA plus patients. An increase in autophagosomes
could reflect either increased autophagic activity
or a reduced turnover; we therefore measured mito-
phagic flux. This is defined as the ratio of the mag-
nitude of the increase in counts of puncta
colocalizing with mitochondria over basal levels,
relative to basal mitophagy,2 in a range of culture
conditions and in the presence of lysosomal inhib-
itors. Growing fibroblasts on starvation (culture
in minimal medium) or glucose-free galactose-
based media (henceforth galactose medium) forces
mitochondria to use oxidative phosphorylation and
increases mitophagy.16 These culture conditions
both generated a greater increase in colocalizing
puncta in biallelic patients than in controls on
both ImageStream (figure 3A) and IN Cell 1000
(figures 3D and 4B and not shown). Lysosomal
inhibitors had a similar effect (figures 3, A, B, and
D, and e-4).
Such conditions may also activate autophagy, con-
sistent with the increase in LC3-ll seen on Western
analysis of cells cultured in galactose (figure e-5),
but this increase is less reproducible.
Effect of OPA1 mutations on mitophagy is modulated by
knocking down proteins involved in mitophagy. To con-
firm that the increased colocalization of LC3 puncta
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with mitochondria involved mitophagy, we knocked
down the essential autophagy protein ATG74 (figure
4A). We therefore performed RNAi on fibroblasts
from DOA plus OPA1(2/2)1–3 patients and con-
trols, obtaining a good reduction in ATG7 protein
levels (figure 4A). Both total and colocalizing LC3
puncta were reduced by ATG7 knockdown in all
conditions (p , 0.001, figure 4B), eliminating the
difference between biallelic patients and controls,
both at baseline and after addition of the lysosomal
inhibitors E64D and pepstatin A.
Effect of idebenone. Exposure of fibroblasts to idebenone,
which modulates the increased mitophagy that we dem-
onstrated in LHON,6 had no effect (figure e-4B).
A mitofusin 2 mutation increases mitochondrial
fragmentation and mitophagy. Mitochondrial depo-
larization and ubiquitination are accepted triggers
Figure 2 A reduction in OPA1 leads to rapid loss of mitochondrial DNA (mtDNA)
Control fibroblasts were treated withOPA1 Pan OPA1 or scramble siRNA. (A) Western blot analysis confirms OPA1 levels were efficiently reduced following
siRNA treatment (blot shows 3 days after knockdown). (B) PicoGreen/tetramethyl rhodamine methyl ester (TMRM) costaining of live fibroblasts treated with
OPA1 siRNA shows a marked loss of mtDNA nucleoids (visible as green puncta) compared to treatment with scramble. In all OPA1 knockdown cells with
mitochondrial fragmentation, a noticeable mitochondrial perinuclear clustering was observed (arrows). (C) Anti-DNA/MitoTracker colabeling of OPA1/
scramble siRNA treated fibroblasts (note that this antibody is recognized to label mtDNA more strongly than nuclear DNA). This confirms the findings
presented in B. (D) Cytochrome oxidase (COX) activity, demonstrated by routine histochemistry, is significantly reduced by day 14. In the panel showing COX
at 14 days in the knockdown, the positions of nuclei are marked with asterisks. By day 5, the distribution of both COX and succinate dehydrogenase (SDH)
activity reflect the mitochondrial perinuclear clustering. Figure e-6 shows that mitochondrial fragmentation occurred without loss of cytochrome c or
alteration of cristae at 48 hours. (E) SiRNA to OPA1 significantly reduced the number of nucleoids visualized by PicoGreen (left panel, p , 0.001, 2-tailed
t test) corresponding tomtDNA content of 8%62%of the control. This was confirmed by quantitative PCR14 days after treatment (right panel, p,0.001,
2-tailed t test). (F) Cell biological basis for relocalization of mitochondria during OPA1 knockdown implies altered transport of fragmented mitochondria.
OPA1 knockdown relocates mitochondria to the microtubule organizing center (MTOC), mediated by microtubules and actin. That this is prevented by
overexpression of p50-dynamitin is shown in figure e-3B. (F.a) Anti-pericentrin (MTOC)/mitofillin (mitochondria) staining shows that siRNA to OPA1 causes
relocation of mitochondria to the MTOC in over 90% of cells as opposed to the scrambled siRNA control (see chart). (F.b) The cell biological basis for
relocalization of mitochondria during OPA1 knockdown implies altered transport mediated by microtubules and actin. Upper left: confirms the presence of
perinuclear mitochondrial clusters followingOPA1 knockdown. Upper right: Disassembly of microtubules by nocodazole treatment (5 mM, 24 hours) rescues
the mitochondrial clustering (p , 0.001). Lower left: Taxotere (5 mM, 24 hours) causes assembly and stabilization of microtubules and hence randomly
distributed mitochondrial clusters (3 clusters in one cell each marked with an arrow, p, 0.01). Lower right: Treatment with cytochalasin D (5 mM, 24 hours),
which depolymerizes actin, also redistributes mitochondria away from theMTOC, although a weak perinuclear clustering was still present (p, 0.01). Each of
these experiments was carried out at least 3 times.
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Figure 3 Analysis of primary cultures from biallelic dominantly inherited optic atrophy (DOA) plus OPA1(2/2)
patients demonstrates increased mitophagy compared to an age-matched control
(A) ImageStream analysis of cultured fibroblasts shows that basal mitophagy is significantly increased in DOA plus OPA1
(2/2)2 and DOA plusOPA1(2/2)3 compared with control both at baseline and following treatment with CQ (all p, 0.01, 2-
tailed t test). (A.a) The number of puncta per cell that were positive for light chain 3 (LC3) (representing both autophago-
somes and autolysosomes) and Tom20 (representing mitochondria). These were counted at baseline in control cells, for
comparison with patients DOA plusOPA1(2/2)2 and 3. Exposure to chloroquine (CQ; 25 mM) overnight blocksmitophagy at
this stage by preventing lysosomal acidification increasing the signal, more so in patients than controls. (A.b, A.c) The counts
of puncta that are positive for both LC3 and LysoID (representing only autolysosomes), counted in control cells, for com-
parison with patient DOA plus OPA1(2/2)1. (A.b) The total number of puncta per cell that were positive for the autolyso-
some markers. (A.c) The counts of these autolysosomes that colocalized with mitochondria (hence autolysosomes involved
in mitophagy) for the same dataset. In all cases there were more counts in the patient than the control. Galactose-based
starvation medium increased the number of LC3/LysoID-positive puncta above baseline. Exposure to 25 mM CQ overnight
did not increase the signal, because it prevents progression of autophagosomes to autolysosomes. Error bars are standard
errors (SEs) (technical replicates). Patient values all significantly greater than control p , 0.01 (2-tailed t test). All are
representative of 1 out of 3 independent replicates. (B) A statistical analysis of 4 consecutive ImageStream runs on all the
patients listed in the table along with 6 controls. The output shows increased mitophagy in patients with severe OPA1
mutations (both biallelic and monoallelic, that is, DOA plus OPA1[2/2] and DOA plus OPA1[1/2]) compared with normal
controls (p 5 0.035). We show one bar per patient group, with each bar’s height (y axis) representing the estimated
difference between a particular patient group and controls. The whiskers on a bar represent the SE of the estimated
difference (61 SE is shown); an approximate 95% confidence interval for the patient-control difference could be calculated
as the bar height62 SEs. The p values in the figure are from the test of the null hypothesis that there is no actual difference
Continued
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for mitophagy, in some situations mitophagy being
amplified by ubiquitinylation of the outer membrane
proteins, mitofusin 1 and 2,25 by Parkin, a ubiquitin
ligase recruited to depolarized mitochondria in con-
nection with PTEN-induced putative kinase 1
(PINK1).26,27
Neither mitochondrial depolarization nor ubiqui-
tination were apparent in our patient fibroblasts (fig-
ure 1E and not shown), so we questioned whether
mitochondrial fragmentation was sufficient in itself to
trigger mitophagy. We therefore studied fibroblasts
from a patient with a dominant negative mutation
in another mitochondrial pro-fusion gene, mitofusin
2 (MFN2). These fibroblasts showed increased frag-
mentation of mitochondria compared to controls
(p 5 0.05), associated with increased mitophagy,
both at baseline and after treatment with the lyso-
somal inhibitor, chloroquine (p , 0.02 and 0.001,
respectively, figure 4C).
DISCUSSION We showed that profound loss of
OPA1 has several effects beyond mitochondrial
fragmentation that potentially contribute to the
pathogenesis of DOA and the onset of clinical
disease. These include increased mitophagy, mito-
chondrial mislocalization, and, potentially, mito-
chondrial dysfunction due to mosaic mtDNA
depletion.
We identified 3 patients who each carried one
frameshift mutation in trans with a novel missense
mutation, designated biallelic OPA1. The term Behr
syndrome has been used for other biallelic OPA1
families with severe phenotypes in which a missense
allele, described as hypomorphic, occurs in trans with
a pathogenic allele.28 Furthermore, both frameshift
mutations caused nonsyndromic DOA with incom-
plete penetrance, yet caused DOA plus when com-
bined with a missense mutation.
OPA1 is a transmembrane protein embedded
within the inner mitochondrial membrane (IMM),
involved in mitochondrial dynamics, specifically in
IMM fusion29 and maintenance of cristae. It is pro-
tective against apoptosis30 and neurodegeneration.31
Mutant cells derived from patients with biallelic
OPA1 mutations not only had a lower level of
OPA1 protein, but there was evidence of significant
mitochondrial fragmentation compared with controls
(figure 1D). A small proportion of these cells with
fragmented mitochondria were profoundly depleted
of mtDNA (figure 1, C and E). High-throughput
quantitative imaging revealed that mitochondrial
fragmentation and mtDNA depletion was also
increased in monoallelic DOA plus patients with
dominantly inherited OPA1 mutations involving
the GTPase domain. While OPA1 depletion is
known to cause mtDNA depletion in neurons,32
the association in fibroblasts is novel. In line with
other investigators, fragmentation and mtDNA
depletion (figure 1E) were not present in fibroblast
cultures from nonsyndromic DOA patients, from the
asymptomatic, obligate carrier relatives of biallelic pa-
tients, or from the controls (table).
Previous investigators found that cultured cells
with even severe respiratory chain defects appear to
experience rather small increases in mitophagy33 and
that defects in respiratory chain function, if present in
OPA1 patients,14 are subtle.7 We suggest that these
subtle defects may reflect the increased level of
mtDNA-depleted mitochondria in cells that we
documented. Two high-throughput imaging systems
(ImageStream and IN Cell 1000) provide objective
evidence of increased colocalization of mitochondria
with autophagosomes and autolysosomes. These are
more sensitive and specific for measuring mitophagy
than conventional fluorescence and electron micros-
copy and Western blotting. Both methods showed
Figure 3 legend, continued:
between a patient group and controls. Useful intuition connecting the hypothesis test with the estimated difference is that
a p value , 0.05 corresponds to a 95% confidence interval not overlapping zero. Uncomplicated symptomatic DOA OPA1
(1/2) and asymptomatic OPA1(1/2) were not different from controls (n 5 1, 2, and 6, respectively). Chloroquine 25 mM
overnight CQ significantly increased the number of LC3 puncta colocalizing with the mitochondrial signal in all individuals in
all experiments (p , 0.001). (C) OPA1 knockdown by siRNA also increases mitophagy. (C.a) Bar chart of ImageStream
output shows that siRNA to OPA1 increases mitophagy. The summed area of LC3 puncta that colocalize with mitochondria
(PDH signal) in fibroblasts treated with OPA1 siRNA is greater than in scramble siRNA and the untreated controls (p5 0.05
and p , 0.01, respectively, both 2-tailed t tests). Mitochondrial mean intensity was also reduced by 5% (not shown). Error
bars are SEs (technical replicates). (C.b) In OPA1 knockdown fibroblasts (OPA1 siRNA) compared to untreated (No siRNA)
and siRNA scramble (Scr siRNA) controls, OPA1 levels are reduced and LC3-II levels are substantially increased relative to
actin by the Western blot analysis. (D) Validation of the increased mitophagic flux, using IN Cell 1000 quantitative fluores-
cencemicroscopy. The number of LC3-positive puncta per cell was quantitated in fibroblasts from biallelicOPA1 patients at
baseline and after 2 hours in the presence of lysosomal protease inhibitors (E64D and pepstatin A, labeled E1P) or after 2
hours starvation in minimal medium compared with age-matched controls. (D.a) Per cell count of LC3-positive puncta
colocalizing with mitochondria (p , 0.0001 and p , 0.005 for baseline compared to lysosomal inhibitors or starvation,
respectively). (D.b) Mean number of total LC3-positive puncta per cell. Each patient had significantly higher counts than
control (p, 0.02) in all conditions, except baseline patient DOA plusOPA1(2/2)3 autophagy and baseline patient DOA plus
OPA1(2/2)1 mitophagy. (D.c) The mitophagic flux is increased in biallelic patients relative to controls (the increase in
colocalization during starvation or lysosomal inhibitors, relative to baseline). Error bars are SEs of technical replicates, all
p values 2-tailed t tests. For further evidence of increased mitophagic flux, see figure e-4A.
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that mitophagy is increased at baseline and following
activation of autophagy in biallelic DOA plus fibro-
blasts, and is reduced by knockdown of the autoph-
agy protein ATG7 (figures 4, A and B, and e-2E).
The increased colocalization of mitochondria and au-
tophagosomes represents increased mitophagic flux
(figure e-4). Mitophagy was thus clearly increased
in patients with monoallelic DOA plus and in
severely affected biallelic OPA1 patients, but not sig-
nificantly in our monoallelic unaffected participants
or in mildly affected, nonsyndromic monoallelic
OPA1 patients. The abundance of OPA1 protein
Figure 4 Effect of OPA1 mutations on mitophagy is impaired by knockdown of ATG7 and recapitulated by
a mitofusin 2 (MFN2 )–dominant negative genotype
(A) Western blot analysis confirms that knockdown of ATG7 by siRNA reduced protein abundance relative to actin in both
patient and control cells. ATG7 5 siRNA to ATG7; DOA 5 dominantly inherited optic atrophy; scr 5 scramble; siRNA 5 no
treatment. (B) The number of colocalizing mitochondrial puncta (mitophagy events per cell, measured by IN Cell 1000) is
significantly increased in fibroblasts from biallelic patients compared to controls at baseline (B.a) (p , 0.001) and after
blocking autophagy with lysosomal inhibitors E64D and pepstatin A (E1P, p 5 0.01). (B.b) Adding E64D and pepstatin A
significantly increased the numbers of colocalizing puncta (p , 0.001) compared to baseline. Knockdown of ATG7 protein
by siRNA significantly reduced the colocalizing puncta (p , 0.001) and eliminated the increase in patients over controls.
Cells were treated with siRNA against ATG7 for 48 hours, then the medium was changed and either solvent or lysosomal
inhibitors, E64D, and pepstatin A were added for 3 days. Error bars are standard errors of technical replicates, all p values
2-tailed t tests. (C) The number of mitophagy events per cell (measured by IN Cell 1000) at baseline (C.a) is significantly
increased in fibroblasts from biallelic DOA plus OPA1(2/2) patients (n5 3) and in a patient with a dominant negativeMFN2
mutation compared to control (p , 0.001 and p , 0.02, respectively). After adding chloroquine (C.b), this was significantly
increased in both the DOA plusOPA1(2/2) patients (n5 3) and theMFN2 fibroblasts compared to control (both p, 0.001).
In neither case was the MFN2 significantly different from biallelic DOA plus OPA1(2/2) patients. Error bars are standard
errors of technical replicates, all p values 2-tailed t tests.
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reflected these differences (figure e-5). This is sup-
ported by electron microscopic findings in 2 mouse
models.17,34
Because mitophagy does not appear to increase
bulk turnover of all mitochondrial components,35
its importance has been called into question. It is
the only type of mitochondrial quality control known
to turn over whole mitochondrial genomes. While it
is not clear that OPA1 mutations directly cause
mtDNAmutations or depletion, altering the dynamic
cycle of mitochondrial fission and fusion is likely to
dysregulate mitophagy and impair mitochondrial
quality.36
Our data show that active mitophagy closely re-
flects the phenotypic severity of DOA plus due to
OPA1 depletion (figures 1E, 3B, and e-5). We
suggest 3 ways in which these could be linked
(figure e-7).
First, the increased mitophagy may be driven by
an excess of fragmented mitochondria, potentially
because of a respiratory chain defect that we did not
detect. This could be beneficial or neutral. This
increase is consistent with type 1 mitophagy,37 a sub-
type that is independent of PINK1 and Parkin.37 This
is because we found no evidence of increased ubiq-
uitination (not shown) and no recruitment of the
mitophagy proteins PINK1 and Parkin. It is thus
plausible that increased fragmentation drives type 1
mitophagy.
Further, microtubule-dependent clustering of
mitochondria, which is also apparent in MFN2
knockdown,38 may also disadvantage the cell, repre-
senting a mitophagic traffic jam. For instance, clus-
tering of fragmented mitochondria may mechanically
obstruct axonal transport of functioning mitochon-
dria or prevent mitochondrial responses to stress
(stress-induced mitochondrial hyperfusion39).
Third, activated mitophagy may increase turnover
of mitochondria and mtDNA. We showed that pro-
found OPA1 knockdown in control fibroblasts causes
progressive loss of mtDNA and eventually mitochon-
drial function (figure 2E). Mitophagy may be exces-
sive in retinal ganglion cells of OPA1 patients,
perhaps increasing demand on lysosomal pathways
or causing mtDNA depletion in key locations.
Indeed, OPA1 depletion recapitulates the effects of
the mitophagy-activating drug, phenanthroline. By
disrupting OPA1 processing, this metalloprotease
inhibitor activates mitophagy excessively, depleting
mitochondria and mtDNA and impairing the selec-
tivity for damaged mtDNA.16
The interplay between these mechanisms remains
to be determined (figure e-7). We showed evidence
that OPA1 depletion affects mitochondrial fragmen-
tation, quality control, and likely microtubular trans-
port, all important determinants of mitochondrial
mass,40 neuronal maturation,32 and health.3 These
could underline the known effects of OPA1 depletion
on neural maturation,32 leading to retinal ganglion
cell loss, optic nerve degeneration, and hence visual
failure. In particular, increased mitophagy is impli-
cated in both LHON and syndromic parkinsonism
caused by OPA mutations.8 These add biological
credibility to our suggestion that dysregulated
mitophagy is important in the pathogenesis of mito-
chondrial optic neuropathies.6 If so, drug modulators
of mitophagy may be useful therapies for this group of
disorders.
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